Loading…
Anlon Healthcare (AHCL)₹26.93−3.23%Pharmaceuticals
In the Sep 2026 quarter (consolidated), Anlon Healthcare reported sales of ₹106 Cr, up 103.7% from Sep 2025, and net profit of ₹17.05 Cr, up 89.0% year on year. For the year to Mar 2026, sales were ₹173 Cr and net profit ₹29.07 Cr.
Company filings, consolidated accounts; latest reported quarter Sep 2026
| Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|
| Sales | 49.14 | 33.10 | 52.19 | 36.10 | 51.18 | 88.21 | 106 |
| Expenses | 31.96 | 26.97 | 37.92 | 22.96 | 35.93 | 71.87 | 79.89 |
| Operating Profit | 17.06 | 6.03 | 14.06 | 12.04 | 15.05 | 16.06 | 25.10 |
| OPM % | 34.9% | 19.0% | 26.0% | 34.9% | 29.9% | 17.9% | 24.0% |
| Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.99 | 0.99 | 0.99 | 1.99 | 0.99 | 0.99 | 0.99 |
| Depreciation | 1.01 | 0.00 | 0.00 | 0.00 | 0.00 | 1.01 | 1.01 |
| Profit before tax | 14.94 | 4.98 | 11.96 | 10.95 | 13.95 | 13.96 | 22.90 |
| Tax % | −7.0% | 29.0% | 25.0% | 51.0% | 23.0% | 39.0% | 27.0% |
| Net Profit | 17.05 | 4.01 | 9.02 | 5.01 | 11.03 | 8.02 | 17.05 |
| EPS (Rs) | 0.41 | 0.08 | 0.17 | 0.09 | 0.19 | 0.12 | 0.24 |
| Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|
| Sales | 120 | 173 | 282 |
| Expenses | 87.88 | 124 | 211 |
| Operating Profit | 32.11 | 48.15 | 68.25 |
| OPM % | 26.9% | 27.9% | 24.2% |
| Other Income | 0.00 | 0.00 | 0.00 |
| Interest | 3.99 | 3.99 | 4.96 |
| Depreciation | 2.01 | 2.01 | 2.02 |
| Profit before tax | 26.89 | 42.86 | 61.76 |
| Tax % | 24.0% | 32.0% | — |
| Net Profit | 21.06 | 29.07 | 41.11 |
| EPS (Rs) | 0.50 | 0.53 | 0.64 |
| Dividend payout % | 0.0% | 0.0% | — |
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 40.11 | 53.14 |
| Reserves | 40.86 | 176 |
| Borrowings | 66.90 | 43.93 |
| Other Liabilities | 33.87 | 99.74 |
| Total Liabilities | 181 | 373 |
| Fixed Assets | 23.02 | 58.10 |
| CWIP | 0.00 | 0.00 |
| Investments | 1.01 | 1.01 |
| Other Assets | 158 | 314 |
| Inventories | 50.01 | 113 |
| Trade receivables | 74.74 | 104 |
| Cash & equivalents | 1.01 | 4.01 |
| Total Assets | 181 | 373 |
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Cash from operating activity | −21.90 | −58.76 |
| Cash from investing activity | 2.01 | −36.16 |
| Cash from financing activity | 18.99 | 118 |
| Net cash flow | −0.99 | 22.93 |
| Capex | 0.54 | 36.52 |
| Free cash flow | −18.97 | −94.99 |
| CFO / OP % | −84.9% | −113.9% |
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Debtor days | 227 | 219 |
| Inventory days | 245 | 392 |
| Days payable | 97 | 148 |
| Cash conversion cycle | 377 | 467 |
| Working capital days | 293 | 418 |
| ROCE % | — | 21.0% |
For the Sep 2026 quarter, Anlon Healthcare reported sales of ₹106 Cr, up 103.7% year on year and net profit of ₹17.05 Cr, up 89.0% year on year. The operating margin was 24.0%.
Anlon Healthcare's sales for the year to Mar 2026 were ₹173 Cr; over the last twelve months they were ₹282 Cr.
Net profit for the year to Mar 2026 was ₹29.07 Cr, and ₹41.11 Cr over the last twelve months. Earnings per share over the same trailing period were ₹0.64.
Anlon Healthcare reported borrowings of ₹43.93 Cr at Mar 2026, against cash and equivalents of ₹4.01 Cr.
Cash from operations was −₹58.76 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹94.99 Cr.